176 related articles for article (PubMed ID: 30205048)
1. Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence.
Boyd AL; Aslostovar L; Reid J; Ye W; Tanasijevic B; Porras DP; Shapovalova Z; Almakadi M; Foley R; Leber B; Xenocostas A; Bhatia M
Cancer Cell; 2018 Sep; 34(3):483-498.e5. PubMed ID: 30205048
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
[TBL] [Abstract][Full Text] [Related]
3. Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
Bruedigam C; Bagger FO; Heidel FH; Paine Kuhn C; Guignes S; Song A; Austin R; Vu T; Lee E; Riyat S; Moore AS; Lock RB; Bullinger L; Hill GR; Armstrong SA; Williams DA; Lane SW
Cell Stem Cell; 2014 Dec; 15(6):775-90. PubMed ID: 25479751
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
5. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
6. Identification of cells of leukemic stem cell origin with non-canonical regenerative properties.
Hollands CG; Boyd AL; Zhao X; Reid JC; Henly C; ElRafie A; Boylan D; Broder E; Kalau O; Johnson P; Mark A; McNicol J; Xenocostas A; Berg T; Foley R; Trus M; Leber B; Garcia-Horton A; Campbell C; Bhatia M
Cell Rep Med; 2024 Apr; 5(4):101485. PubMed ID: 38582086
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
8. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
Kikushige Y; Miyamoto T
Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
[TBL] [Abstract][Full Text] [Related]
9. Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia.
Zhang CC; Yan Z; Pascual B; Jackson-Fisher A; Huang DS; Zong Q; Elliott M; Fan C; Huser N; Lee J; Sung M; Sapra P
Neoplasia; 2018 Jan; 20(1):1-11. PubMed ID: 29172076
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Residual Leukemia Cells after Chemotherapy.
Vu LP; Kharas MG
Cancer Cell; 2018 Sep; 34(3):353-355. PubMed ID: 30205040
[TBL] [Abstract][Full Text] [Related]
11. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
[TBL] [Abstract][Full Text] [Related]
12. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.
Naldini MM; Casirati G; Barcella M; Rancoita PMV; Cosentino A; Caserta C; Pavesi F; Zonari E; Desantis G; Gilioli D; Carrabba MG; Vago L; Bernardi M; Di Micco R; Di Serio C; Merelli I; Volpin M; Montini E; Ciceri F; Gentner B
Nat Commun; 2023 Mar; 14(1):1285. PubMed ID: 36890137
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
15. Tracing the origins of relapse in acute myeloid leukaemia to stem cells.
Shlush LI; Mitchell A; Heisler L; Abelson S; Ng SWK; Trotman-Grant A; Medeiros JJF; Rao-Bhatia A; Jaciw-Zurakowsky I; Marke R; McLeod JL; Doedens M; Bader G; Voisin V; Xu C; McPherson JD; Hudson TJ; Wang JCY; Minden MD; Dick JE
Nature; 2017 Jul; 547(7661):104-108. PubMed ID: 28658204
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia.
Strese S; Hassan SB; Velander E; Haglund C; Höglund M; Larsson R; Gullbo J
Oncotarget; 2017 Jan; 8(4):6341-6352. PubMed ID: 27974676
[TBL] [Abstract][Full Text] [Related]
17. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
[TBL] [Abstract][Full Text] [Related]
19. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
20. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro.
Tafuri A; Andreeff M
Leukemia; 1990 Dec; 4(12):826-34. PubMed ID: 2243506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
